Liu Y et al. |
[Effect of Herba Epimedii Flavone on expression of OPG and RANKL in rat osteoblasts]. |
2005 |
Zhong Yao Cai |
pmid:16568663
|
Kozaki K |
[Current concepts of vascular calcification]. |
2005 |
Nihon Ronen Igakkai Zasshi |
pmid:16408509
|
Liu JM et al. |
Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. |
2005 |
Calcif. Tissue Int. |
pmid:15455183
|
Schoppet M et al. |
TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. |
2005 |
Biochem. Biophys. Res. Commun. |
pmid:16288714
|
Michael H et al. |
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. |
2005 |
J. Bone Miner. Res. |
pmid:16294275
|
Nicholls BM et al. |
Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor. |
2005 |
J. Bone Miner. Res. |
pmid:16294279
|
Yeung RS |
Bones, blood vessels, and the immune system: what's the link? |
2005 |
J. Rheumatol. |
pmid:16265680
|
Simonini G et al. |
Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. |
2005 |
J. Rheumatol. |
pmid:16265708
|
Kim SM et al. |
Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. |
2005 |
Clin. Endocrinol. (Oxf) |
pmid:16268814
|
Minenna G et al. |
[RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. |
2005 |
Recenti Prog Med |
pmid:16229324
|
Pantsulaia I et al. |
Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees. |
2005 |
Cytokine |
pmid:16213155
|
Dovio A et al. |
Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? |
2005 |
J. Endocrinol. Invest. |
pmid:16550717
|
Tarquini R et al. |
Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. |
2005 |
Biomed. Pharmacother. |
pmid:16275499
|
Cozzani M et al. |
Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. |
2005 |
Prog Orthod |
pmid:16276433
|
Gaudio A et al. |
Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? |
2005 |
J. Endocrinol. Invest. |
pmid:16277162
|
Taubman MA et al. |
Immune response: the key to bone resorption in periodontal disease. |
2005 |
J. Periodontol. |
pmid:16277573
|
Bartold PM et al. |
Periodontitis and rheumatoid arthritis: a review. |
2005 |
J. Periodontol. |
pmid:16277578
|
Kaji H et al. |
Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. |
2005 |
Horm. Metab. Res. |
pmid:16278780
|
Gonnelli S et al. |
Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. |
2005 |
J. Endocrinol. Invest. |
pmid:16117195
|
Zhou Z et al. |
Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. |
2005 |
Cancer |
pmid:16121404
|
Ashcroft AJ and Carding SR |
RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. |
2005 |
Gut |
pmid:16099805
|
Lems WF and Bijlsma JW |
[Clinical implications of new insights into the regulation of bone resorption]. |
2005 |
Ned Tijdschr Geneeskd |
pmid:16104110
|
Daroszewska A and Ralston SH |
Genetics of Paget's disease of bone. |
2005 |
Clin. Sci. |
pmid:16104845
|
Rogers A and Eastell R |
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. |
2005 |
J. Clin. Endocrinol. Metab. |
pmid:16105967
|
Wise GE et al. |
CSF-1 regulation of osteoclastogenesis for tooth eruption. |
2005 |
J. Dent. Res. |
pmid:16109994
|
Huang P et al. |
[In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast]. |
2005 |
Zhonghua Wai Ke Za Zhi |
pmid:16083587
|
Kwon OH et al. |
The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. |
2005 |
Biochem. Biophys. Res. Commun. |
pmid:16083856
|
Hayton MJ et al. |
Involvement of adenosine 5'-triphosphate in ultrasound-induced fracture repair. |
2005 |
Ultrasound Med Biol |
pmid:16085103
|
von Knoch F et al. |
Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. |
2005 |
J Biomed Mater Res A |
pmid:16088891
|
Li J et al. |
[Effect of raloxifene and estradiol on the biological function and osteoprotegerin expression of osteoblasts in vitro]. |
2005 |
Di Yi Jun Yi Da Xue Xue Bao |
pmid:16027068
|
Kahl KG et al. |
Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. |
2005 |
Osteoporos Int |
pmid:15300363
|
Gallant MA et al. |
Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. |
2005 |
J. Bone Miner. Res. |
pmid:15765187
|
Zannettino AC et al. |
Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. |
2005 |
J. Cell. Physiol. |
pmid:15799029
|
Tada T et al. |
Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. |
2005 |
Int. J. Cancer |
pmid:15800904
|
Mandelin J et al. |
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. |
2005 |
J. Rheumatol. |
pmid:15801030
|
Holmen SL et al. |
Essential role of beta-catenin in postnatal bone acquisition. |
2005 |
J. Biol. Chem. |
pmid:15802266
|
Bernstein CN et al. |
Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. |
2005 |
Inflamm. Bowel Dis. |
pmid:15803021
|
Mitani M et al. |
Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. |
2005 |
Int. J. Mol. Med. |
pmid:15806305
|
Voskaridou E and Terpos E |
Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. |
2005 |
Eur. J. Haematol. |
pmid:15777350
|
Mossetti G et al. |
Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. |
2005 |
Bone |
pmid:15777635
|
Janssens K et al. |
An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. |
2005 |
Bone |
pmid:15777670
|
Fábrega E et al. |
Osteoprotegerin and RANKL in alcoholic liver cirrhosis. |
2005 |
Liver Int. |
pmid:15780054
|
Fukushima H et al. |
IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. |
2005 |
Bone |
pmid:15780952
|
Regmi A et al. |
Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. |
2005 |
Bone |
pmid:15780954
|
Abrahamsen B et al. |
Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. |
2005 |
Bone |
pmid:15781001
|
Moe SM et al. |
Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). |
2005 |
Kidney Int. |
pmid:15882271
|
Ueland T et al. |
Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. |
2005 |
Circulation |
pmid:15883214
|
Sabokbar A et al. |
Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. |
2005 |
J. Orthop. Res. |
pmid:15885469
|
Morony S et al. |
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. |
2005 |
Endocrinology |
pmid:15845617
|
Rhee EJ et al. |
The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. |
2005 |
Am. J. Obstet. Gynecol. |
pmid:15846185
|
Rasmussen LM and Ledet T |
Osteoprotegerin and diabetic macroangiopathy. |
2005 |
Horm. Metab. Res. |
pmid:15918117
|
Tanabe N et al. |
IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. |
2005 |
Life Sci. |
pmid:15921993
|
Zhou YQ et al. |
[OPG and OPGL expression in condyle cartilage of temporomandibular joint following anterior disc displacement]. |
2005 |
Shanghai Kou Qiang Yi Xue |
pmid:16155701
|
Crisafulli A et al. |
Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. |
2005 |
Clin. Sci. |
pmid:15926884
|
Holen I et al. |
Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? |
2005 |
Breast Cancer Res. Treat. |
pmid:16155791
|
Mahamed DA et al. |
G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. |
2005 |
Diabetes |
pmid:15855336
|
Hong JS et al. |
Maternal plasma osteoprotegerin concentration in normal pregnancy. |
2005 |
Am. J. Obstet. Gynecol. |
pmid:16157103
|
Leder BZ and Finkelstein JS |
Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. |
2005 |
Osteoporos Int |
pmid:15856361
|
Galli C et al. |
Comparison of human mandibular osteoblasts grown on two commercially available titanium implant surfaces. |
2005 |
J. Periodontol. |
pmid:15857069
|
Stolina M et al. |
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. |
2005 |
J. Bone Miner. Res. |
pmid:16160733
|
Suzuki K et al. |
Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. |
2005 |
Diabetes Res. Clin. Pract. |
pmid:15860239
|
Yasuda H |
[OPG, anti-rANKL antibody]. |
2005 |
Nippon Rinsho |
pmid:16164225
|
Choi BK et al. |
Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. |
2005 |
J. Periodontol. |
pmid:15898943
|
Moschen AR et al. |
The RANKL/OPG system and bone mineral density in patients with chronic liver disease. |
2005 |
J. Hepatol. |
pmid:16143421
|
Carda C et al. |
Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint. |
2005 |
Tissue Cell |
pmid:15899507
|
Maïmoun L et al. |
Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. |
2005 |
Calcif. Tissue Int. |
pmid:15812577
|
Ulrich-Vinther M and Andreassen TT |
Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. |
2005 |
Calcif. Tissue Int. |
pmid:15812581
|
Ishizuka K et al. |
Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. |
2005 |
Neurosci. Lett. |
pmid:15814197
|
Cui N et al. |
Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. |
2005 |
Clin. Cancer Res. |
pmid:15814653
|
Wang L et al. |
Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. |
2005 |
Am. J. Physiol. Endocrinol. Metab. |
pmid:15585587
|
Byrne FR et al. |
CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. |
2005 |
Gut |
pmid:15591508
|
Zehnder AF et al. |
Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. |
2005 |
Laryngoscope |
pmid:15630389
|
Kees M et al. |
Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. |
2005 |
Thromb. Haemost. |
pmid:15630493
|
Mochizuki S et al. |
[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis]. |
2005 |
Clin Calcium |
pmid:15632471
|
Sakakura Y et al. |
Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice. |
2005 |
J. Anat. |
pmid:16191162
|
Oh KW et al. |
Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. |
2005 |
Clin. Endocrinol. (Oxf) |
pmid:15638876
|
Meng XM et al. |
[Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw]. |
2005 |
Zhonghua Kou Qiang Yi Xue Za Zhi |
pmid:16191370
|
Khosla S |
Magic bullets to kill nasty osteoclasts. |
2005 |
Endocrinology |
pmid:16009971
|
Tabuchi M et al. |
Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. |
2005 |
Calcif. Tissue Int. |
pmid:16193235
|
Feng X |
RANKing intracellular signaling in osteoclasts. |
2005 |
IUBMB Life |
pmid:16012047
|
Kusumi A et al. |
Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. |
2005 |
J. Bone Miner. Metab. |
pmid:16133687
|
Moran CS et al. |
Association of osteoprotegerin with human abdominal aortic aneurysm progression. |
2005 |
Circulation |
pmid:15939823
|
Deftos LJ |
Treatment of Paget's disease--taming the wild osteoclast. |
2005 |
N. Engl. J. Med. |
pmid:16135831
|
Li F et al. |
Annexin II stimulates RANKL expression through MAPK. |
2005 |
J. Bone Miner. Res. |
pmid:15940368
|
Cundy T et al. |
Recombinant osteoprotegerin for juvenile Paget's disease. |
2005 |
N. Engl. J. Med. |
pmid:16135836
|
Sen O et al. |
The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. |
2005 |
Neurol. Res. |
pmid:15949247
|
Bock O et al. |
Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. |
2005 |
Br. J. Haematol. |
pmid:15982347
|
Heinrich J et al. |
CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. |
2005 |
Arch. Oral Biol. |
pmid:16137499
|
Fiore CE et al. |
Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. |
2005 |
Osteoporos Int |
pmid:15983730
|
Avignon A et al. |
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. |
2005 |
Diabetes Care |
pmid:16123486
|
Amizuka N et al. |
Histological evaluation for "bone quality" on two mouse models with different bone remodeling. |
2005 |
J. Bone Miner. Metab. |
pmid:15984413
|
Ziegler S et al. |
Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. |
2005 |
Metab. Clin. Exp. |
pmid:15988704
|
Manganelli P et al. |
OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? |
2005 |
Clin. Rheumatol. |
pmid:15583970
|
Belibasakis GN et al. |
The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells. |
2005 |
Infect. Immun. |
pmid:15618171
|
Liu XH et al. |
Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. |
2005 |
Endocrinology |
pmid:15618359
|
Cao JJ et al. |
Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. |
2005 |
J. Bone Miner. Res. |
pmid:15619667
|
Liu PY et al. |
A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. |
2005 |
J. Clin. Endocrinol. Metab. |
pmid:15623811
|
Marotte H et al. |
Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. |
2005 |
Arthritis Res. Ther. |
pmid:15642135
|
Katsuyama H et al. |
Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL and RANK in osteoblastic MC3T3E1 cells. |
2005 |
Int. J. Mol. Med. |
pmid:15647836
|
Matayoshi T et al. |
Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. |
2005 |
Biochem. Biophys. Res. Commun. |
pmid:15649411
|